Views: 1,392 | Downloads:
23
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy, Safety and Acceptability of a Seven-Day, Transdermal Estradiol Patch for Estrogen Replacement Therapy
Jarupanich T 
,
Lamlertkittikul S ,
Chandeying V
,
Lamlertkittikul S ,
Chandeying V TAPNARONG JARUPANICH, MD*,
SURACHAI LAMLERTKITTIKUL, MD*,
VERAPOL CHANDEYING, MD**
Objectives
: To evaluate the efficacy, safety and acceptability of a seven-day, transdermal
estradiol patch, in the treatment of menopausal symptoms.
Design:
Open-label trial.
Setting
: Hat Y ai Regional Hospital, Thailand.
Subjects
: Hysterectomized women with surgical or natural menopause.
Method:
The clients received a 12.5 cm2 matrix patchเธŽ, containing 3.9 mg of estradiol deliver-
ing 0.05 mg/day, once a week for six months. The efficacy, safety, and acceptability were evaluated at
the end of 1-, 3-and 6-months.
Results
: Six-month responses were analyzed among 50 enrolled patients. The mean estradiol
level/Follicle Stimulating Hormone/Lutienizing Hormone were 27.88/70.03/31.19, 44.08/53.37/26.86,
and 42.43/48.53/24.39 pg/ml, miU/L, miU/L at admission, 1-and 3-months, respectively. The average
climacteric score was 27.18, 16.60, 12.78, and 12.18 at admission, 1-,3-and 6-month, respectively. At
least 94 per cent of patches were not dislodged more than one quarter. The most common skin irrita-
tion was itching, followed by erythema, vesicle, and burning sensation. The patches were generally well
tolerated, and acceptability was satisfactory.
Conclusion
: Transdermal estradiol patch effectively reduced the severity of menopausal
symptoms, measured by modified climacteric score. Adhesion was found to be excellent. In actual clini-
cal practice, the transdermal patch should be appropriately introduced to tolerant users.
Key word
: Transdermal Estradiol, Estrogen Replacement Therapy, Efficacy, Safety, Acceptability
SURACHAI LAMLERTKITTIKUL, MD*,
VERAPOL CHANDEYING, MD**
Objectives
: To evaluate the efficacy, safety and acceptability of a seven-day, transdermal
estradiol patch, in the treatment of menopausal symptoms.
Design:
Open-label trial.
Setting
: Hat Y ai Regional Hospital, Thailand.
Subjects
: Hysterectomized women with surgical or natural menopause.
Method:
The clients received a 12.5 cm2 matrix patchเธŽ, containing 3.9 mg of estradiol deliver-
ing 0.05 mg/day, once a week for six months. The efficacy, safety, and acceptability were evaluated at
the end of 1-, 3-and 6-months.
Results
: Six-month responses were analyzed among 50 enrolled patients. The mean estradiol
level/Follicle Stimulating Hormone/Lutienizing Hormone were 27.88/70.03/31.19, 44.08/53.37/26.86,
and 42.43/48.53/24.39 pg/ml, miU/L, miU/L at admission, 1-and 3-months, respectively. The average
climacteric score was 27.18, 16.60, 12.78, and 12.18 at admission, 1-,3-and 6-month, respectively. At
least 94 per cent of patches were not dislodged more than one quarter. The most common skin irrita-
tion was itching, followed by erythema, vesicle, and burning sensation. The patches were generally well
tolerated, and acceptability was satisfactory.
Conclusion
: Transdermal estradiol patch effectively reduced the severity of menopausal
symptoms, measured by modified climacteric score. Adhesion was found to be excellent. In actual clini-
cal practice, the transdermal patch should be appropriately introduced to tolerant users.
Key word
: Transdermal Estradiol, Estrogen Replacement Therapy, Efficacy, Safety, Acceptability
Download:
PDF